Lilly Inks $1.3 Billion Deal to Bring in AI for Obesity Drug Discovery
- August 15, 2025
Eli Lilly and Company will collaborate with Superluminal Medicines—a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock G protein-coupled receptors (GPCRs)—the companies announced August 14.
ARTICLE TAGS
You must be logged in to access this content.